URGN FY 2025 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$110M+21.4% YoY

Gross Profit

$97M88.7% margin

Operating Income

-$125M-113.7% margin

Net Income

-$153M-139.8% margin

EPS (Diluted)

$-3.19

Cash Flow

Operating Cash Flow

-$162M

Free Cash Flow

-$163M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$200M

Total Liabilities

$306M

Stockholders' Equity

-$105M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$110M	$90M	+21.4%
Gross Profit	$97M	$82M	+19.4%
Operating Income	-$125M	-$97M	-29.0%
Net Income	-$153M	-$127M	-21.0%